MET exon 14 Mutations Encode a Hyperactive Kinase and Therapeutic Target in Lung Adenocarcinoma

被引：0
|
作者：
Peled, Nir [1 ]
Lu, Xinyuan [2 ]
Greer, John [2 ]
Wu, Wei [2 ]
Choi, Peter [3 ]
Berger, Alice [3 ]
Hann, Byron [2 ]
Meyerson, Matthew [4 ,5 ]
Collisson, Eric [2 ]
机构：
[1] Rabin Med Ctr, Tel Aviv, Israel
[2] UCSF, San Francisco, CA USA
[3] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[4] Broad Inst Harvard & Mit, Dana Farber Canc Inst, Boston, MA USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
MET; Resistance; Targeted therapy; Mouse model;
D O I：
10.1016/j.jtho.2016.11.1323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.03b042
引用
收藏
页码：S961 / S961
页数：1
相关论文
共 50 条
  • [1] MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
    Lu, Xinyuan
    Peled, Nir
    Greer, John
    Wu, Wei
    Choi, Peter
    Berger, Alice H.
    Wong, Sergio
    Jen, Kuang-Yu
    Seo, Youngho
    Hann, Byron
    Brooks, Angela
    Meyerson, Matthew
    Collisson, Eric A.
    CANCER RESEARCH, 2017, 77 (16) : 4498 - 4505
  • [2] MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma
    Zhang, Meng
    Li, Guichao
    Sun, Xiangjie
    Ni, Shujuan
    Tan, Cong
    Xu, Midie
    Huang, Dan
    Ren, Fei
    Li, Dawei
    Wei, Ping
    Du, Xiang
    HUMAN PATHOLOGY, 2018, 77 : 108 - 115
  • [3] MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer
    Baldacci, S.
    Kherrouche, Z.
    Descarpentries, C.
    Wislez, M.
    Dansin, E.
    Furlan, A.
    Tulasne, D.
    Cortot, A. B.
    REVUE DES MALADIES RESPIRATOIRES, 2018, 35 (08) : 796 - 812
  • [4] MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
    Lung, Jrhau
    Hung, Ming-Szu
    Lin, Yu-Ching
    Lee, Kam-Fai
    Jiang, Yuan Yuan
    Huang, Shao-Lan
    Fang, Yu-Hung
    Lu, Ming-Shian
    Lin, Chin-Kuo
    Yang, Tsung-Ming
    Lin, Paul Yann
    Hsieh, Meng-Jer
    Tsai, Ying Huang
    PLOS ONE, 2019, 14 (08):
  • [5] c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas
    Mignard, Xavier
    Ruppert, Anne-Marie
    Antoine, Martine
    Vasseur, Julie
    Girard, Nicolas
    Mazieres, Julien
    Moro-Sibilot, Denis
    Fallet, Vincent
    Rabbe, Nathalie
    Thivolet-Bejui, Francoise
    Rouquette, Isabelle
    Lantuejoul, Sylvie
    Cortot, Alexis
    Saffroy, Raphael
    Cadranel, Jacques
    Lemoine, Antoinette
    Wislez, Marie
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : 1962 - 1967
  • [6] MET receptor tyrosine kinase as a therapeutic anticancer target
    Stellrecht, Christine M.
    Gandhi, Varsha
    CANCER LETTERS, 2009, 280 (01) : 1 - 14
  • [7] A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
    Santarpia, Mariacarmela
    Massafra, Marco
    Gebbia, Vittorio
    D'Aquino, Antonio
    Garipoli, Claudia
    Altavilla, Giuseppe
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (03) : 1536 - +
  • [8] Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer
    Pruis, M. A.
    Geurts-Giele, W. R. R.
    von der Thusen, J. H.
    Meijssen, I. C.
    Dinjens, W. N. M.
    Aerts, J. G. J., V
    Dingemans, A. M. C.
    Lolkema, M. P.
    Paats, M. S.
    Dubbink, H. J.
    LUNG CANCER, 2020, 140 : 46 - 54
  • [9] Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation
    Rotow, Julia K.
    Woodard, Gavitt A.
    Urisman, Anatoly
    McCoach, Caroline E.
    Bivona, Trever G.
    Elicker, Brett M.
    Jablons, David M.
    Blakely, Collin M.
    CLINICAL LUNG CANCER, 2019, 20 (02) : E137 - E141
  • [10] Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
    Takamori, Shinkichi
    Matsubara, Taichi
    Fujishita, Takatoshi
    Ito, Kensaku
    Toyozawa, Ryo
    Seto, Takashi
    Yamaguchi, Masafumi
    Okamoto, Tatsuro
    THORACIC CANCER, 2021, 12 (06) : 978 - 980
12345